Related Experiment Videos
Granisetron: the second serotonin-receptor antagonist
1College of Pharmacy, University of Florida, Gainesville, USA.
The Annals of Pharmacotherapy
|December 1, 1995
Summary
Granisetron effectively prevents chemotherapy-induced nausea and vomiting, showing comparable efficacy to ondansetron. This selective serotonin3-receptor (5-HT3) antagonist offers a safe option for managing these distressing side effects.
Area of Science:
- Pharmacology
- Clinical Trials
- Oncology
Background:
- Chemotherapy-induced nausea and vomiting (CINV) are significant adverse effects impacting patient quality of life.
- Serotonin (5-HT3) receptor antagonists have revolutionized CINV management.
- Granisetron is a second-generation 5-HT3 antagonist available in the US.
Purpose of the Study:
- To review granisetron's pharmacology, pharmacokinetics, clinical efficacy, and safety.
- To critically analyze clinical trials of granisetron.
- To compare granisetron with other antiemetic agents, including ondansetron.
Main Methods:
- Searched MEDLINE and CANCERLIT databases (1966-1995 and 1991-1995).
- Included English-language literature using terms "granisetron" and "granisetron (rn)".
- Prioritized studies with unique critical information and recent publications.
Main Results:
- Granisetron is superior to conventional antiemetics for CINV prevention.
- Granisetron demonstrates efficacy comparable to ondansetron in preventing CINV.
- Optimal dosing and cost-effectiveness require further consideration.
Conclusions:
- Granisetron is a safe and effective antiemetic for managing chemotherapy-induced nausea and vomiting.
- Granisetron represents a valuable therapeutic option in supportive cancer care.